What’s Propelling Ironwood Pharmaceuticals, Inc. (IRWD) to Increase So Much?

February 15, 2018 - By Peter Erickson

Investors sentiment decreased to 1.25 in 2017 Q3. Its down 0.06, from 1.31 in 2017Q2. It worsened, as 24 investors sold Ironwood Pharmaceuticals, Inc. shares while 32 reduced holdings. 13 funds opened positions while 57 raised stakes. 154.60 million shares or 6.92% more from 144.60 million shares in 2017Q2 were reported.
Great West Life Assurance Can has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Proshare Advsr Limited Liability Corp holds 85,330 shares or 0.01% of its portfolio. 2,900 are owned by Qs Lc. Pictet Asset Mngmt Limited has invested 0.12% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). 60,999 are owned by Fincl Bank Of Montreal Can. Citigroup Incorporated holds 133,928 shares. Sector Gamma As has 1.83 million shares. Swiss Bancorp invested in 0% or 210,500 shares. Jpmorgan Chase & invested in 19,610 shares or 0% of the stock. Commercial Bank Of Nova Scotia invested in 0% or 19,000 shares. California State Teachers Retirement System holds 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 215,473 shares. Nj State Employees Deferred Compensation Plan reported 0.03% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Bancshares Of America Corp De reported 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). The France-based Bnp Paribas Asset Management has invested 0.24% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Parallax Volatility Advisers Limited Partnership holds 94,216 shares.

Since August 18, 2017, it had 0 insider buys, and 3 insider sales for $983,540 activity. The insider Consylman Gina sold $2,968. McHugh Julie had sold 1,500 shares worth $24,240 on Tuesday, September 5. OLANOFF LAWRENCE S sold 2,000 shares worth $32,300.

The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a huge mover today! The stock increased 7.56% or $1.095 during the last trading session, reaching $15.585. About 1.73M shares traded or 13.94% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 57.40% since February 15, 2017 and is uptrending. It has outperformed by 40.70% the S&P500.
The move comes after 5 months positive chart setup for the $2.33B company. It was reported on Feb, 15 by Barchart.com. We have $16.21 PT which if reached, will make NASDAQ:IRWD worth $93.36M more.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on February, 20. They expect $-0.22 EPS, down 83.33 % or $0.10 from last year’s $-0.12 per share. After $-0.18 actual EPS reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 22.22 % negative EPS growth.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Ironwood Pharmaceuticals had 37 analyst reports since August 6, 2015 according to SRatingsIntel. Barclays Capital maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Wednesday, February 22. Barclays Capital has “Equal Weight” rating and $16 target. Cowen & Co maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, August 21 with “Buy” rating. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Buy” rating given on Friday, July 15 by Mizuho. Mizuho maintained it with “Buy” rating and $20 target in Friday, November 4 report. As per Wednesday, December 6, the company rating was downgraded by Mizuho. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Friday, October 6 with “Buy” rating. The firm has “Buy” rating given on Monday, October 10 by Mizuho. Cowen & Co maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Thursday, July 20. Cowen & Co has “Buy” rating and $2000 target. On Tuesday, January 9 the stock rating was maintained by Mizuho with “Hold”. Mizuho maintained the shares of IRWD in report on Thursday, July 20 with “Buy” rating.

More recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Gurufocus.com which released: “Broderick Brian C Buys Ironwood Pharmaceuticals Inc, EOG Resources Inc …” on February 02, 2018. Also Businesswire.com published the news titled: “Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor …” on February 15, 2018. Businesswire.com‘s news article titled: “Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor …” with publication date: February 01, 2018 was also an interesting one.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.33 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.